Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

CRO Role In Clinical Trial Research Questioned By NEJM Article

Executive Summary

The increasing use of contract research organizations in the clinical trial process could increase skepticism among physicians and the public about study results, a New England Journal of Medicine "Health Policy Report" maintains.

You may also be interested in...



Conflict-Of-Interest Rules Should Set Limits On Payments – ACC President

Conflict-of-interest guidelines should include specific limits on payments from companies to investigators, outgoing American College of Cardiology President Bruce Fye, MD, Mayo Clinic, told the association's annual meeting March 31 in Chicago

Conflict-Of-Interest Rules Should Set Limits On Payments – ACC President

Conflict-of-interest guidelines should include specific limits on payments from companies to investigators, outgoing American College of Cardiology President Bruce Fye, MD, Mayo Clinic, told the association's annual meeting March 31 in Chicago

ACCME Certification Of Rx Firms Challenged In JAMA, Defended By PhRMA

The Accreditation Council for Continuing Medical Education's pending "firewall" policy eliminates any concerns about pharmaceutical companies acting as certified CME providers, Pharmaceutical Research & Manufacturers of America President Alan Holmer maintained in the April 18 issue of the Journal of the American Medical Association.

Related Content

Latest Headlines
See All
UsernamePublicRestriction

Register

PS036088

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel